Uniqure (NASDAQ:QURE) Cut to Neutral at Guggenheim

Guggenheim downgraded shares of Uniqure (NASDAQ:QURE) from a buy rating to a neutral rating in a research note published on Monday morning, BenzingaRatingsTable reports.

A number of other equities research analysts have also recently commented on the stock. Piper Jaffray Companies started coverage on shares of Uniqure in a research note on Friday, April 12th. They set an overweight rating and a $80.00 price objective on the stock. Cantor Fitzgerald reaffirmed an overweight rating and set a $94.00 price objective (up previously from $81.00) on shares of Uniqure in a research note on Monday, July 8th. Zacks Investment Research raised shares of Uniqure from a hold rating to a buy rating and set a $79.00 price objective on the stock in a research note on Friday, July 12th. HC Wainwright set a $73.00 target price on Uniqure and gave the company a buy rating in a research report on Monday, July 8th. Finally, Janney Montgomery Scott reiterated a buy rating on shares of Uniqure in a research report on Tuesday, June 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $78.18.

Shares of NASDAQ QURE opened at $58.65 on Monday. The firm has a market cap of $2.27 billion, a PE ratio of -25.06 and a beta of 1.05. Uniqure has a 12 month low of $21.98 and a 12 month high of $82.49. The stock’s 50 day moving average price is $72.59. The company has a quick ratio of 9.51, a current ratio of 9.51 and a debt-to-equity ratio of 0.38.

Uniqure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, July 29th. The biotechnology company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.08). The firm had revenue of $2.47 million for the quarter, compared to analyst estimates of $1.53 million. Uniqure had a negative return on equity of 48.90% and a negative net margin of 1,032.06%. On average, equities analysts forecast that Uniqure will post -3 EPS for the current year.

In other Uniqure news, Director Philip Astley-Sparke sold 6,000 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $63.63, for a total value of $381,780.00. Following the transaction, the director now owns 18,872 shares in the company, valued at approximately $1,200,825.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Matthew C. Kapusta sold 8,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $58.38, for a total value of $467,040.00. Following the completion of the transaction, the chief executive officer now owns 421,730 shares in the company, valued at approximately $24,620,597.40. The disclosure for this sale can be found here. Insiders have sold a total of 30,000 shares of company stock worth $2,040,020 in the last quarter. Insiders own 2.91% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. FMR LLC lifted its holdings in Uniqure by 0.8% in the 1st quarter. FMR LLC now owns 3,688,791 shares of the biotechnology company’s stock valued at $220,036,000 after purchasing an additional 29,629 shares in the last quarter. Pearl River Capital LLC purchased a new position in Uniqure in the 1st quarter valued at $32,000. Harvest Group Wealth Management LLC purchased a new position in Uniqure in the 1st quarter valued at $26,000. Vivo Capital LLC purchased a new position in Uniqure in the 1st quarter valued at $10,757,000. Finally, Henry James International Management Inc. lifted its holdings in Uniqure by 20.4% in the 1st quarter. Henry James International Management Inc. now owns 90,786 shares of the biotechnology company’s stock valued at $5,415,000 after purchasing an additional 15,412 shares in the last quarter. Institutional investors own 60.27% of the company’s stock.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Recommended Story: How is diluted EPS different from basic EPS?

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.